Evaluating biological assets
At the annual accounts or at the beginning of the year, the biological assets must be
evaluated at their fair value minus point-of-sale expenses. Although, if on the initial
estimation, the fair value cannot be estimated realistically, the biological asset must be
estimated at its costs, minus collected amortization and any depreciation collected loss. Once
the fair value becomes realistic, the asset must be estimated at its fair value, minus the pointof-
sale costs. If there is an active market for a certain asset or agricultural produce, the quote
on that market is actually an appropriate basis for estimating the assets’ fair value. If there is
no such market, the following criteria are used for the fair value estimation:
- the most recent market transaction price
- market prices of similar assets
- sector standards
The third step in determining the fair value is using the purchase and production costs as
parameters for estimating the fair value. This implies that on the purchase or production date,
the asset already suffered a reduced biological transformation, or it had an insignificant
influence on the assets’ value. In these 2 cases, the purchase and production costs are
approximate to the fair value. The purchase and production costs of assets are determined as
purchase price minus purchase price cuttings. The production costs of assets that are produced
by the entity include all production costs as well as indirect costs. IAS 41 stipulates that in
order to determinate the fair value, one must calculate the updated value of net cash flows
resulted from the assets’ usage. This procedure is available only if the fair value of the asset
cannot be realistically determined, neither it can be determined using an active market, nor the
purchase and production costs are eliminated. The asset’s net cash flows will be updated
Evaluating biological assets
At the annual accounts or at the beginning of the year, the biological assets must be
evaluated at their fair value minus point-of-sale expenses. Although, if on the initial
estimation, the fair value cannot be estimated realistically, the biological asset must be
estimated at its costs, minus collected amortization and any depreciation collected loss. Once
the fair value becomes realistic, the asset must be estimated at its fair value, minus the pointof-
sale costs. If there is an active market for a certain asset or agricultural produce, the quote
on that market is actually an appropriate basis for estimating the assets’ fair value. If there is
no such market, the following criteria are used for the fair value estimation:
- the most recent market transaction price
- market prices of similar assets
- sector standards
The third step in determining the fair value is using the purchase and production costs as
parameters for estimating the fair value. This implies that on the purchase or production date,
the asset already suffered a reduced biological transformation, or it had an insignificant
influence on the assets’ value. In these 2 cases, the purchase and production costs are
approximate to the fair value. The purchase and production costs of assets are determined as
purchase price minus purchase price cuttings. The production costs of assets that are produced
by the entity include all production costs as well as indirect costs. IAS 41 stipulates that in
order to determinate the fair value, one must calculate the updated value of net cash flows
resulted from the assets’ usage. This procedure is available only if the fair value of the asset
cannot be realistically determined, neither it can be determined using an active market, nor the
purchase and production costs are eliminated. The asset’s net cash flows will be updated
การแปล กรุณารอสักครู่..
